Eosinophils in bronchial mucosa of asthmatics after allergen challenge: Effect of anti-IgE treatment

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 1, 2009, Pages 72-80

  Van Rensen, E L J ^a   Evertse, C E ^a   Van Schadewijk, W A A M ^a   Van Wijngaarden, S ^a   Ayre, G ^b   Mauad, T ^c   Hiemstra, P S ^a   Sterk, P J ^a   Rabe, K F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Allergen challenge; Anti IgE; Asthma; Biopsies; Human

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; METHACHOLINE; PLACEBO;

ADULT; ARTICLE; ASTHMA; BRONCHOSCOPY; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EOSINOPHIL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS;

ADOLESCENT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHIAL PROVOCATION TESTS; CD4-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; MALE; RECEPTORS, IGE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149113160     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01881.x     Document Type: Article

References (36)

1. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005 115 : 459 465.
2. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989 320 : 271 277.
3. Pollart SM, Chapman MD, Fiocco GP, Rose G, Platts-Mills TA. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol 1989 83 : 875 882.
4. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001 164 : S1 S5.
5. Stokes J, Casale TB. Rationale for new treatments aimed at IgE immunomodulation. Ann Allergy Asthma Immunol 2004 93 : 212 217.
6. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM et al. Humanization of an antibody directed against IgE. J Immunol 1993 151 : 2623 2632.
7. MacGlashan DW Jr., Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997 158 : 1438 1445.
8. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003 112 : 1147 1154.
9. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006 117 : 1493 1499.
10. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997 155 : 1835 1840.
11. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997 155 : 1828 1834.
12. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001 108 : 184 190.
13. Milgrom H, Fick RB Jr., Su JQ, Reimann JD, Bush RK, Watrous ML et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999 341 : 1966 1973.
14. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001 18 : 254 261.
15. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 316.
16. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004 170 : 583 593.
17. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993 16 : 5 40.
18. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993 16 : 53 83.
19. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003 19 : 491 498.
20. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993 147 : 1126 1131.
21. in 't Veen JC, de Gouw HW, Smits HH, Sont JK, Hiemstra PS, Sterk PJ et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J 1996 9 : 2441 2447.
22. Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987 135 : 264 267.
23. Sont JK, Willems LN, Evertse CE, Hooijer R, Sterk PJ, Van Krieken JH. Repeatability of measures of inflammatory cell number in bronchial biopsies in atopic asthma. Eur Respir J 1997 10 : 2602 2608.
24. Sont JK, De Boer WI, Van Schadewijk WA, Grunberg K, Van Krieken JH, Hiemstra PS et al. Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue. Am J Respir Crit Care Med 2003 167 : 1496 1503.
25. Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999 160 : 1023 1027.
26. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002 110 : 68 71.
27. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003 131 : 46 52.
28. Lambrecht BN. Dendritic cells and the regulation of the allergic immune response. Allergy 2005 60 : 271 282.
29. Lechmann M. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol 2002 23 : 273 275.
30. Geijtenbeek TB. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000 100 : 575 585.
31. Wenzel SE, Fowler AA III., Schwartz LB. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis 1988 137 : 1002 1008.
32. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008 31 : 143 178.
33. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000 356 : 2144 2148.
34. Birrell MA, Battram CH, Woodman P, McCluskie K, Belvisi MG. Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways. Respir Res 2003 4 : 3.
35. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999 54 : 403 408.
36. Sont JK, Willems LNA, Bel EH, van Krieken HJM, Vandenbroucke JP, Sterk PJ et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Resp Crit Care Med 1999 159 : 1043 1051.